A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience
Issue link: https://innovationscns.epubxp.com/i/499434
Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 2 , N U M B E R 3 – 4 , S U P P L E M E N T A , M A R C H – A P R I L 2 0 1 5 ] 40S 56. Vancampfort D, Probst M, Sweers K, et al. Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatr Scand. 2011;123:423–430. 57. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697–701. 58. Walther S, Horn H, Razavi N, et al. Quantitative motor activity differentiates schizophrenia subtypes. Neuropsychobiology. 2009b;60:80–86. 59. Docx L, Sabbe B, Provinciael P, et al. Quantitative psychomotor dysfunction in schizophrenia: a loss of drive, impaired movement execution or both? Neuropsychobiology. 2013;68:221–227. 60. Walther S, Ramseyer F, Horn H, et al. Less structured movement patterns predict severity of positive syndrome, excitement, and disorganization. Schizophr Bull. 2014;40:585–591. 61. Walther S, Federspiel A, Horn H, et al. Alterations of white matter integrity related to motor activity in schizophrenia. Neurobiol Dis. 2011;42:276–283. 62. Walther S, Horn H, Koschorke P, et al. Increased motor activity in cycloid psychosis compared to schizophrenia. World J Biol Psychiatry. 2009;10:746–751. 63. Walther S, Koschorke P, Horn H, Strik W. Objectively measured motor activity in schizophrenia challenges the validity of expert ratings. Psychiatry Res. 2009c;169:187–190. 64. Wichniak A, Skowerska A, Chojnacka-Wojtowicz J, et al. Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone. J Psychiatr Res. 2011;45:1381–1386. 65. Walther S, Horn H, Razavi N, et al. Higher motor activity in schizophrenia patients treated with olanzapine versus risperidone. J Clin Psychopharmacol. 2010;30:181–184. 66. Bracht T, Heidemeyer K, Koschorke P, et al. Comparison of objectively measured motor behavior with ratings of the motor behavior domain of the Bern Psychopathology Scale (BPS) in schizophrenia. Psychiatry Res. 2012;198:224–229. 67. Peralta V, Cuesta MJ. The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine. Prim Care Companion J Clin Psychiatry. 2010;12. 68. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012;69:904–912. 69. Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry. 2004;161:1705–1708. 70. Roffman JL, Weiss AP, Purcell S, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63:42–48. 71. Hill M, Shannahan K, Jasinski S, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res. 2011;127:41–45. 72. Roffman JL, Brohawn DG, Nitenson AZ, et al. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull. 2013;39(2):330–338. 73. Roffman JL, Lamberti JS, Achtyes E, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013 May;70(5):481–489. 74. Zhang JP, Lencz T, Geisler S, et al. Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophr Res. 2013;146:285–288. 75. Castellanos FX, Di Martino A, Craddock RC, et al. Clinical applications of the functional connectome. NeuroImage. 2013;80:527–540. 76. McGrath CL, Kelley ME, Holtzheimer PE, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013;70:821–829. 77. Eack SM, Hogarty GE, Cho RY, et al. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry. 2010;67:674–682. 78. Pillai A, Kale A, Joshi S, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol. 2010;13:535–539. 79. Mondelli V, Cattaneo A, Belvederi Murri M, et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry. 2011;72:1677–1684. 80. Chan MK, Guest PC, Levin Y, et al. Converging evidence for blood-based biomarkers in schizophrenia: an update. Int Rev Neurobiol. 2001;101:95–144. 81. Schwarz E, Guest PC, Steiner J, et al. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry. 2012;2:e82. 82. Aberg KA, McClay JL, Nerella S, et al. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry. 2014;71:255–264.